CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease Toulouse, May 23rd 2025 Cell-Easy, a Contract Development and Manufacturing Organization (CDMO) specialized in advanced cell therapies, announces that its allogeneic adipose-derived mesenchymal stem cell product, CellReady®, will be investigated in a
Cell-Easy Expands its GMP Cell Therapy Manufacturing Facility to Support Growing Client Demand. New state-of-the-art class-B cleanrooms, development labs, and logistics upgrades accelerate scalable production of autologous & allogeneic cell therapies in compliance with FDA/EMA standards. Toulouse, France –April 9th – Cell-Easy, a leading European Contract Development and Manufacturing Organization (CDMO) specializing
CHU Toulouse receives CTA Approval to initiate ALLOFIST, a Phase 1/2 Trial based on Cell-Easy’s proprietary adipose-derived MSC in Patients suffering from Crohn Disease. Toulouse, France, January 15, 2025 The long-term partnership between Cell-Easy and Toulouse University Hospital (CHU Toulouse) continues to bear fruits, bringing innovative MSC-based therapies to local
Cell-Easy Expands US Footprint with Key Contract Signing for Master Cell Bank (MCB) and Working Cell Bank (WCB) Manufacturing Services. Toulouse, France, May 14, 2024 – Cell-Easy, a European Contract Development and Manufacturing Organization (CDMO) specializing in Cell Therapy, announces a significant milestone with the signing of a Cell
Accelerating Patient Access to Advanced Cell-based Therapies through the Signature of a Service Agreement between the French CDMO and the Toulouse University Hospital (CHU Toulouse) Toulouse, France, April 18, 2024 – This agreement between the two parties opens great perspectives for Biotechs, providing them with seamless access to patients who
The accumulated expertise among various programs as well as our local partnerships have been the foundation to close such a deal. I’m a true believer that our positioning can be beneficial for other biotech seeking to easily access patient cohorts. Alexis Delbaere Tweet About Cell-Easy Cell-Easy is a science-centric CDMO
EU regulatory approval to administer Adipose-derived mesenchymal Stem Cells (ASCs) in patients with ischemic digital ulcers marks key milestone for partners Toulouse, France, November 16, 2023 – Cell-Easy, a French Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies, and the Toulouse University Hospital, today announce that they
